^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
BI 765179
i
Other names: BI 765179, BI-765179, BI765179
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Boehringer Ingelheim
Drug class:
CD137 agonist, FAP inhibitor
Related drugs:
5ms
A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) (clinicaltrials.gov)
P1, N=160, Recruiting, Boehringer Ingelheim | Trial completion date: Mar 2026 --> Nov 2026 | Trial primary completion date: Jun 2025 --> Feb 2026
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
ezabenlimab (BI 754091) • BI 765179
11ms
A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) (clinicaltrials.gov)
P1, N=160, Suspended, Boehringer Ingelheim | Recruiting --> Suspended
Trial suspension • Combination therapy • Metastases
|
FAP (Fibroblast activation protein, alpha)
|
ezabenlimab (BI 754091) • BI 765179
12ms
A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) (clinicaltrials.gov)
P1, N=160, Recruiting, Boehringer Ingelheim | Trial completion date: Jul 2025 --> May 2026 | Trial primary completion date: Sep 2024 --> Jul 2025
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
FAP (Fibroblast activation protein, alpha)
|
ezabenlimab (BI 754091) • BI 765179
2years
A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) (clinicaltrials.gov)
P1, N=150, Recruiting, Boehringer Ingelheim | Trial completion date: Jan 2025 --> Jul 2025 | Trial primary completion date: Mar 2024 --> Sep 2024
Trial completion date • Trial primary completion date • Combination therapy
|
FAP (Fibroblast activation protein, alpha)
|
ezabenlimab (BI 754091) • BI 765179
over2years
A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) (clinicaltrials.gov)
P1, N=150, Recruiting, Boehringer Ingelheim | Not yet recruiting --> Recruiting
Clinical • Enrollment open • Combination therapy
|
FAP (Fibroblast activation protein, alpha)
|
ezabenlimab (BI 754091) • BI 765179
almost3years
A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) (clinicaltrials.gov)
P1, N=150, Not yet recruiting, Boehringer Ingelheim
Clinical • New P1 trial • Combination therapy
|
FAP (Fibroblast activation protein, alpha)
|
ezabenlimab (BI 754091) • BI 765179
Share via
